AngioDynamics Inc (NASDAQ:ANGO) reported its fiscal third-quarter 2026 results, delivering a performance that narrowly surpassed analyst revenue expectations while significantly beating on the bottom line. The company's strategic focus on its higher-margin medical technology portfolio continues to fuel growth, though the market's initial reaction in pre-market trading was negative.
Earnings and Revenue Versus Estimates
The medical device maker's results for the quarter ended February 28, 2026, presented a mixed but generally positive picture against Wall Street forecasts. The company reported a pro forma net sales figure of $78.4 million, representing an 8.9% year-over-year increase. This topline figure slightly exceeded the analyst consensus estimate of approximately $78.3 million.
The more notable beat came on profitability. AngioDynamics reported an adjusted loss per share of $0.07. This was a substantial improvement over the analyst estimate for a loss of $0.11 per share, indicating better-than-expected cost management and operational execution.
Key Q3 2026 Results vs. Estimates:
- Reported Revenue: $78.4 million
- Estimated Revenue: $78.3 million
- Result: Beat
- Reported Adj. EPS: -$0.07
- Estimated Adj. EPS: -$0.11
- Result: Beat
Market Reaction and Price Action
Despite the earnings beat, shares of AngioDynamics were down approximately 3.7% in pre-market trading following the report. This negative knee-jerk reaction may reflect profit-taking after a period of strength—the stock is up about 14.8% over the past two weeks—or perhaps investor focus on near-term headwinds like gross margin pressure and cash flow timing. It underscores the market's complex weighing of quarterly beats against longer-term guidance and execution challenges.
Quarterly Performance Highlights
The core narrative from the quarter remains the powerful growth of AngioDynamics' Med Tech segment, which is central to its transformation strategy. This segment grew 19.0% year-over-year to $37.3 million, driven by strong performances across its key platforms.
- Auryon (atherectomy): Sales of $16.3 million, up 17.9%.
- Mechanical Thrombectomy (AlphaVac & AngioVac): Sales of $11.5 million, up 17.9%.
- NanoKnife (irreversible electroporation): Sales of $7.6 million, up 21.0%.
CEO Jim Clemmer highlighted the "standout performance" of the thrombectomy portfolio and noted that NanoKnife is "accelerating adoption" following the establishment of a new CPT reimbursement code for prostate procedures.
The company's profitability metrics showed progress. Adjusted EBITDA was $1.8 million, up from $1.3 million in the prior-year quarter. However, GAAP gross margin contracted by 110 basis points to 52.9%, which management attributed to tariffs, inflation, and costs tied to its manufacturing transition—all factors it stated were in line with expectations.
Updated Financial Guidance
Management raised its full-year fiscal 2026 outlook across several key metrics, expressing confidence in its operational trajectory. The new guidance was issued alongside a note that cash flow for the year may be "slightly negative" due to a planned inventory build to mitigate potential sterilization vendor disruptions, though the company reaffirmed its positive cash generation pathway.
Fiscal 2026 Guidance Update (vs. Previous):
- Net Sales: $313.5 - $315.5 million (increased from $312 - $314 million)
- Med Tech Growth: 15% - 17% (increased from 14% - 16%)
- Adjusted EBITDA: $10.0 - $12.0 million (increased from $8.0 - $10.0 million)
- Adjusted EPS: ($0.30) – ($0.23) (narrowed from ($0.33) – ($0.23))
This upgraded outlook compares favorably to current analyst projections, which estimate full-year sales of approximately $319.1 million and an EPS loss of $0.30. For the upcoming fourth quarter, analysts are modeling a loss of $0.08 per share on sales of $82.8 million.
Conclusion
AngioDynamics' third-quarter results underscore a company successfully executing a pivot toward high-growth technology platforms. The double-digit expansion in its Med Tech business and a significant bottom-line beat are clear positives. While pre-market trading indicated some investor caution, potentially related to gross margin pressure and cash flow timing, management's decision to raise its full-year guidance suggests underlying business momentum remains strong. The company's ability to continue scaling its key growth drivers like Auryon, AlphaVac, and NanoKnife will be critical as it aims for sustained profitability.
For more detailed historical earnings data and future analyst projections, you can review the ANGO earnings page and analyst forecasts.
Disclaimer: This article is for informational purposes only and does not constitute investment advice, financial analysis, or a recommendation to buy or sell any security. Investors should conduct their own research and consult with a qualified financial advisor before making any investment decisions.